anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The traditional Chinese medicine extraction compositions for the treatment of FGID or intestinal irritable syndrome, preparation method and in the application of preparing in medicine. Each component adopts bulk drug extract, does is weight ratio: Rhizoma Atractylodis Macrocephalae extract I? 3 ~ 29, Rhizoma Atractylodis Macrocephalae extract II? 18 ~ 57, radix paeoniae alba extraction 13 ~ 53, dried orange peel extracts 6 ~ 32, Radix Saposhnikoviae extract 2 ~ 27. Rhizoma Atractylodis Macrocephalae extract I is the way of distillation or supercritical extraction extract; Rhizoma Atractylodis Macrocephalae extract II is water extract; Radix paeoniae alba extraction is ethanol extract; Dried orange peel extracts is ethanol extract; Radix Saposhnikoviae extract water extraction is got or supercritical extract. The present invention has overcome the traditional view of &#34; Chinese medicine compound prescription decoct altogether or always extract be better than each medicinal material extract respectively &#34;, is processed and has significantly been improved pharmacological effect, the quality control of the composition of being more convenient for by the optimum organization of each medicinal substances extract. The composition for the treatment of FGID of the present invention or intestinal irritable syndrome has produced beyond thought effect.
Clinical trials are defined, managed and evaluated according to an overall end-to-end system. The central authority creates protocol meta-models and makes them available to clinical trial protocol designers. Each meta-model includes a short list of preliminary patient elligibility attributes which are appropriate for a particular disease category. The protocol designer chooses the appropriate meta-model, and encodes the clinical trial protocol, including eligibility and patient workflow, whithin the selected meta-model. The resulting protocol database is stored together with databases of other protocols in a library of protocol databases. Sponsors and individual clinical sites have controlled access to the protocols. Study sites make reference to the pertinent protocol databases to which they have access in the protocol database library in order to perform patient eligibility screening. Once a patient is enrolled into a study, the protocol database indicates to the clinician what tasks are to be performed at each patient visit. These tasks can include both patient management tasks and data management tasks. The workflow graph advantageously also instructs the proper time for the clinician to obtain a patient&#39;s informed consent. The system reports patient progress to study sponsors, who can then monitor the progress of the trial, and to a central authority which can then generate performance metrics. Advantageously, a common controlled medical terminology database is used by all components of the system.
NEW MATERIAL:A quinone of formula I (R is lower alkyl, lower alkoxy; A is -CH2-, -CO-, formula II; n is 2-8) or its ester. EXAMPLE:2,3,5-Trimethyl-6-(6&#39;-hydroxyhexyl)-1,4-benzoquinone. USE:Medicine. It shows an excellent action on lysosome membranes as well as action to control physiological living body resistance, especially actions to accelerate immunization and to relax smooth muscles and is used as an immune adjuvant. Further, it has an appropriate level of hydrophilicity and is readily prepared into drugs with high stability to light and acid. PREPARATION:The compound of formula I is obtained by oxidizing a compound of formula III (X is H, hydroxyl which may be protected; Y is hydroxyl which may be protected) or its ester with an oxidizing agent such as potassium nitrosodisulfonate in a solvent such as a diluted alkali solution, preferably at 0-2.5 deg.C for 0.5-5hr.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an anti-allergic composition comprising a plant of the genus Rosa of the family Rosaceae and an ingredient derived from the plant and α-cyclodextrin and to provide a food and drink and an additive for the food and drink comprising the composition.  &lt;P&gt;SOLUTION: The anti-allergic composition comprises (1) an extract from the plant of the genus Rosa of the family Rosaceae, (2) the plant of the genus Rosa of the family Rosaceae and (3) at least one kind of the extract from the plant of the genus Rosa of the family Rosaceae and/or a fermented material obtained by fermenting and culturing the plant of the genus Rosa of the family Rosaceae and the α-cyclodextrin. The food and drink comprises the anti-allergic composition. The additive for the food and drink comprises the anti-allergic composition. The anti-allergic composition, etc., inhibit and ameliorate allergic diseases and can continuously be used over a long period without causing adverse effects, etc., peculiar to medicines.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
A method is provided for determining an orientation of nerve fibres relative to a non-physiological electric field. Patient medical image data is acquired, which describes a patient medical image of an anatomical body part of a patient&#39;s body. The anatomical body part includes nerve tissue comprising white matter nerve fibres. Diffusion image data is acquired, which describes a diffusion-enhanced image of the anatomical body part. Atlas data is acquired, which describes a spatial distribution of grey value-based tissue classes in a model body part representing a model of the anatomical body part. Based on the patient image data, the diffusion image data, and the atlas data, fibre orientation data is determined. The fibre orientation data describes an orientation of the white matter nerve fibres. Electric field orientation data is acquired, which describes an orientation of the non-physiological electric field. The non-physiological electric field is an electric field simulated around a simulated electrode virtually placed in a predetermined spatial relationship relative to the anatomical body part. Based on the fibre orientation data and the electric field orientation data, relative orientation data is determined. The relative orientation data describes a relative orientation between the orientation of the white matter nerve fibres and the orientation of the electric field.
PURPOSE:To obtain the subject compound having antiviral activity in high efficiency by coupling a 1-thioglycoside derivative with a pyrimidine base in the presence of an activation agent. CONSTITUTION:The objective compound of formula III or formula IV is produced by coupling a phenyl-2,3-dideoxy-1-thio-D-glycero-pentofuranoside of formula I (R is silyl) with a pyrimidine base of formula II (R&lt;1&gt; is methyl or ethyl; X is O, NH or N-acetyl; R&lt;2&gt; is H or methyl) in the presence of an activation agent (e.g. N-bromosuccinimide) in an aprotic organic solvent (e.g. dichloromethane) in an inert gas atmosphere (e.g. argon) at -100 to 0 deg.C. The amount of the activation agent is 1-2mol based on 1mol of the compound of formula I and the pyrimidine base is preferably bistrimethylsilyl compound of N-acetylcytosine.
Process for management of batches of haematopoietic-system components belonging to human subjects from whom these batches have been collected for deferred use. Each batch of haematopoietic-system components associated with a subject is packed and stored in a cryogenic storage site among a plurality of cryogenic storage sites (S A , . . . S L ) and then transferred on request from this storage site to a cell treatment center for re-use on said subject or on said subject&#39;s parent. A gathering of both personal data relating to the subject from whom the batch was collected and of data relating to the collection is associated with each collection phase (I).
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a coloring matter for a pharmaceutical composition preventing it from discoloration even if used therein, to provide a method for producing the coloring matter, to provide the pharmaceutical composition prevented from discoloration attributable to the coloring matter and a medicament therein after storage, and to provide a method for preventing the pharmaceutical composition from discoloration, particularly effective in the presence of moisture.  &lt;P&gt;SOLUTION: The powdery coloring matter is such one as to be coated with one or more coating agents selected from fatty acid, fatty acid metal salt, fatty acid ester and waxes. This coloring matter can prevent the pharmaceutical composition from discoloration even if used therein. The method for producing the coloring matter is provided. The pharmaceutical composition comprising the coloring matter and the medicament and prevented from discoloration after storage is provided. The method for preventing the pharmaceutical composition from discoloration is also provided.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
A medical monitoring device, operating system, and method is provided for managing administration of medical treatment regimens for treating a patient&#39;s medical conditions. The device stores medication schedule data, treatment data, patient query data, and patient response data. The device includes a controller for controlling modes of operation of the device, controlling access of the memory, controlling display of the treatment data and the patient query data on a display, receiving and processing patient response data, tracking timing, and providing scheduled medication alarm signals. The device further includes dedicated keys interfaced with the controller. Each dedicated key is associated with one of the medical treatment regimens, and initiates the display of treatment messages relating to the associated medical treatment regimen. Successive actuation of each dedicated key initiates the display of further treatment messages relating to the associated medical treatment regimen. The device further includes soft function keys interfaced with the controller. The soft function keys signal the controller, commanding it to execute different modes of operation of the medical monitoring device. The device provides scheduled medication alarm signals that alert the user concerning prescribed medications due to be taken.
PCT No. PCT/EP88/01083 Sec. 371 Date Aug. 20, 1990 Sec. 102(e) Date Aug. 20, 1990 PCT Filed Nov. 29, 1988 PCT Pub. No. WO90/06299 PCT Pub. Date Jun. 14, 1990.The invention relates to new phenylethanolamines of general formula    &lt;IMAGE&gt;  (I)  wherein A represents a straight-chained or branched alkylene group, B represents a bond, an alkylene group, a carbonyl or hydroxymethylene group, R1 represents a hydrogen atom, a halogen atom or a trifluoromethyl group, R2 represents a hydrogen atom or an amino group, R3 represents a cyano group, a hydrogen, chlorine or bromine atom and R4 represents a hydrogen or halogen atom, an alkyl, hydroxy, alkoxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group or an alkoxy group substituted in the end position by a carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, hydroxy, alkoxy, amino, alkylamino, dialkylamino, pyrrolidino, piperidino or hexamethyleneimino group, the optical isomers and diastereoisomers and acid addition salts thereof. The new compounds of formula I, the optical isomers and diastereoisomers and acid addition salts thereof, particularly the physiologically acceptable acid addition salts thereof with inorganic or organic acids, have valuable pharmacological properties, namely an effect on the metabolism, preferably the effect of lowering blood sugar and reducing body fat and they may also be used as performance enhancers in animals. The new compounds of general formula I above may be prepared by methods known per se.
FIELD: medicine. ^ SUBSTANCE: application of a fluridon herbicide (1-methyl-5 (,,-trifluoro-m-tolyl)-3-phenylpyridinon-4) of the structural formula (I) as an agent for treatment of oncologic diseases with a disposable dosage from 0.1 mg to 5 g on reception to 3 times a day is offered. It is possible to take fluridon in the form of a dry powder or as an aqueous solution in rectal, intravenous or intraperitoneal manner, in the form of ointment, candles, or inhalant. Efficiency of treatment of oncologic diseases is shown: adenocarcinoma, melanoma with metastasises, carcinoma, non-Hodgkin&#39;s lymphoma, liver cancer, glioblastoma, and sarcoma. ^ EFFECT: development of a substance which suppresses proliferation of cancer cells more effectively than doxorubicine, does not cause by-effects in patients at its use. ^ 8 cl, 5 tbl, 13 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a drug reducing the amount of an anesthetic used by enhancing the anesthetic depth in balanced anesthesia, rapidly awakening after completing administration and ameliorating symptoms.  &lt;P&gt;SOLUTION: A combined agent is prepared by combining the anesthetic with landiolol hydrochloride. The landiolol hydrochloride represented by the formula has short-time type β&lt;SB&gt;1&lt;/SB&gt;receptor blocking actions and further actions on deepening the depth of the anesthetic. Thereby, since the amount of other anesthetics used can be reduced by using the landiolol hydrochloride, the agent is useful as an anesthetic adjuvant. Since this compound has a short half-life, the awakening time from the anesthesia is short and refreshing awakening can be promoted for patients. Thereby, the symptoms during awakening can be ameliorated.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
A medical information management system and corresponding methods are described for providing access to healthcare records. The system includes a database system comprising healthcare records of a patient, a healthcare workstation coupled to the database system and an authentication system comprising a processor coupled to the database system. The healthcare workstation is located at a treatment facility or point of treatment that is remote to the database system. The authentication system generates an image of a finger of the patient at the point of treatment, and generates from the image an identification number. The authentication system compares the identification number to a stored number corresponding to the patient, and authenticates the patient&#39;s identity when the comparison produces a match between the identification number and stored number. Access to the healthcare records is controlled via the healthcare workstation in response to authentication of the patient.
Automated modular physical health testing systems and associated devices and methods are disclosed herein. A modular system configured in accordance with embodiments of the present technology can include, for example, a housing, a communications hub, and a plurality of physical health testing devices. The housing integrates the communications hub and stores the plurality of physical health testing devices. The physical health testing devices are in wired and/or wireless communication with the communications hub. Each physical health testing device is configured to generate physical health data of a user and to transmit generated physical health data to the communication hub and/or a user&#39;s mobile device. The modular physical health testing system provides an automated physical exam that can be performed at user&#39;s homes or other convenient locations.
&lt;P&gt;PROBLEM TO BE SOLVED: To make a work of pharmacists more efficient by enabling data confirmation relevant to past drug preparation.  &lt;P&gt;SOLUTION: A portable terminal 30a executes a waiting patient display processing for list-displaying patients accepted yet drug-unprepared based on data stored in respective files 364-367 by authenticating the pharmacists for operation, and displays a list of accepted and drug-prepared patients as a waiting patient list. When a change of the display order is instructed, a display order changing processing is executed to redisplay the patient list in the changed display order. When a rank setting is instructed, a ranking processing is executed to add set rank to each accepted patient, and the waiting patient list is redisplayed. When display of past direction data of the patient selected is instructed in the waiting patient list, the past direction data corresponding to the past direction data display patient is acquired from a past direction data file 367 to be displayed on a display part 33.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain the subject promoter useful for cosmetic, etc., capable of promoting percutaneous absorption by taking advantage of blood cleaning action, blood vessel dilating effects, biochemically reducing action and protein enzymatically hydrolyzing action, by using an extract of Impatience balsamina L. with an alcohol. SOLUTION: This promoter comprises an extract of Impatience balsamina L. (of the genus Impatience of the family Balsaminaceae) with an alcohol. The extracted solution is obtained, for example, by immersing 2-5 pts.wt. of the whole plant of Impatience balsamina L. in 10 pts.wt. of an aqueous solution ethyl alcohol having &gt;=10 degrees for two weeks to a half year and separating the residue by a means such as dry mesh method, etc. The concentration of ethyl alcohol in the extracted solution is preferably 5-30%.
PURPOSE:To provide the subject compound having remarkably increased antibacterial activity especially against clinical isolate, free from convulsion-inducing action caused by the combined use with anti-inflammatory agent and useful as an antibacterial agent, anti-tumor agent and therapeutic agent for AIDS. CONSTITUTION:The compound of formula I (R&lt;1&gt; is H or lower alkyl; R&lt;2&gt; is H, carboxylic acid ester residue, etc.; C atom labeled with * is asymmetric C atom having absolute configuration of R or S) and its salt, e.g. (1S,3&#39;S)-7-(3- amino-1-pyrrolidinyl)-6-fluoro-1-methyl-4-oxo-1H,4H-[1,3]thiazeto[3,2- a]quinoline-3- carboxylic acid. The compound can be produced by reducing and dehalogenating an optically active 8-halogenothiazetoquinoline-3-carboxylic acid derivative of formula II (X is halogen) and, as necessary, hydrolyzing the product. The compound of formula II is also a new compound, which can be produced e.g. by reacting a compound of formula III (Y is X) with a compound of formula IV and halogenating the reaction product.
The invention provides for a wireless and data logging capable bio sensor system worn by individuals that transmits and stores biometric information gathered from multiple and diverse sensors on or near the individual&#39;s body. Through these sensors and its transmitters this device can convey and store vast amounts of information pertaining to an individual&#39;s physical condition and neurological state as well as the effects of physical activity on the individual&#39;s body. This data collection and sensory system could also be applied to biomechanical animal studies. Versions of this invention applied to the medical industry will allow medical specialists and patients to monitor health conditions in real time. This system will log historical biometric data to create an accurate mosaic of physical performances and conditions over a period of time. Logging of individual biometric data will create a unique and key biometric signature for each user.
This invention relates to a Cisplatin preparation. It comprises a Cisplatin injection solution accommodated in a light blocking plastic container. The Cisplatin injection solution is a pH 4.5 to 6.5 solution containing chloride ions in an amount of 0.45 w/v% or more. The plastic container has such light blocking property that for example, light of 470 nm or below is blocked but is permeable for oxygen. Alternatively, it provides a Cisplatin preparation comprising a light blocking plastic container. Wherein, the Cisplatin injection solution is accommodated and packed with a light blocking packaging material. The preparation in accordance with the invention ensures easy handling, it can be safely used while certainly avoiding the danger of tissue damage of personnel&#39;s skin at handling. In addition, it excels in storage stability with reducing deactivation or deterioration.
PURPOSE:To provide a fat emulsion containing a non-steroidal antiinflammatory analgesic substance, a simple lipid, a phospholipid and water, enabling the selective transfer of a drug into the focus in high efficiency without lowering the pharmacological action of the drug and capable of keeping the blood concentration of the drug. CONSTITUTION:The objective fat emulsion has an average particle diameter of &lt;200nm and contains (A) an active amount of a non-steroidal antiinflammatory analgesic substance, e.g. indomethacin, aspirin or ibuprofen, especially preferably their fat-soluble derivatives, (B) 0.5-30%(W/V) (based on the whole composition) of a simple lipid (e.g. neutral lipid such as refined soybean oil, corn oil and triolein) and sterol derivative such as cholesteryl oleate, (C) 0.15-2 pts.wt. (based on 1 pt.wt. of the component B) of a phospholipid and (D) a proper amount of water. The non-specific incorporation by an endothelial cell system can be avoided to enable the reduction of the necessary dose of the drug.
PURPOSE: To improve antifoulancy by manufacturing a orthodontic appliance including a ligator, a rotational wedge, a redressment module, etc., by using specified substances and providing a specified color difference. CONSTITUTION: A ligator 10 for orthodontic appliance is manufactured by using one or more substances among thermoplastic rubber block copolymer, polyurethane, polyurea, polyurethane/urea, silicone substance, ethylene-propylene dimer rubber, ethylene-propylene monomer rubber and fluoroelastomer. In the ligator 10, when the thickness is 2mm and an aperture for illumination of 2.5mm is used, the Hunter&#39;s color difference is at most 30 in comparison with a Hunter&#39;s standard white tile. In addition, in comparison with a substance before immersion in a mustard soln., the Hunter&#39;s color difference becomes at most 33 after it is immersed in the mustard soln. for 30min. It is possible thereby to improve antifoulancy to foods and drinks such as musturd, tea and coffee.
PURPOSE:To obtain a readily available and safe thrombolytic agent for oral use containing a plasmin produced by Bacillus NATTO. CONSTITUTION:A thrombolytic agent containing a plasmin contained in &#39;NATTO&#39; (fermented soybeans), Bacillus NATTO or a culture thereof as an active ingredient. The plasmin is preferably used as an extract obtained by extracting the &#39;NATTO&#39; or Bacillus NATTO with water or an aqueous solution, such as aqueous solution of salts, at pH 6-11 and &lt;=60 deg.C or as a supernatant prepared by filtering a culture, if in the form of a liquid culture. The dose thereof is, e.g., generally 0.1-10g, preferably 0.2-5g administered in about 1-3 divided portions a day for a fraction, obtained by extracting the &#39;NATTO&#39; with a physiological saline solution and subjecting the resultant extract solution to gel filtration and having about 20,000mol.wt. The pharmaceutical is divided into the dose unit and prepared. The afore-mentioned enzyme has effects on enhancement of tissue plasminogen activator (TPA) production originally inherent in living bodies and accelerating fibrinolytic activity in blood by oral administration.